Hefei Lifeon Pharmaceutical Co Ltd Market Cap ($501.27 Million)
Market Cap & Net Worth: Hefei Lifeon Pharmaceutical Co Ltd (003020)
Hefei Lifeon Pharmaceutical Co Ltd market cap. Hefei Lifeon Pharmaceutical Co Ltd (SHE:003020) has a market capitalization of $501.27 Million (CN¥3.43 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11907 globally and #3388 in its home market, demonstrating a -3.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hefei Lifeon Pharmaceutical Co Ltd's stock price CN¥15.01 by its total outstanding shares 228218618 (228.22 Million). Also see Hefei Lifeon Pharmaceutical Co Ltd (003020) cash flow conversion for how efficiently the company converts equity into cash flow.
Hefei Lifeon Pharmaceutical Co Ltd Market Cap History (2020–2026)
Hefei Lifeon Pharmaceutical Co Ltd market cap history from 2020 to 2026. Data shows change from $528.91 Million to $501.27 Million (-0.37% CAGR). Check 003020 stock price and chart for real-time trading data and today's change.
Hefei Lifeon Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hefei Lifeon Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hefei Lifeon Pharmaceutical Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.56x
Hefei Lifeon Pharmaceutical Co Ltd's market cap is 0.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.23x
Hefei Lifeon Pharmaceutical Co Ltd's market cap is 5.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $528.91 Million | $1.89 Billion | $135.12 Million | 0.28x | 3.91x |
| 2021 | $712.72 Million | $2.27 Billion | $172.23 Million | 0.31x | 4.14x |
| 2022 | $667.21 Million | $2.58 Billion | $209.25 Million | 0.26x | 3.19x |
| 2023 | $765.85 Million | $1.90 Billion | $226.67 Million | 0.40x | 3.38x |
| 2024 | $602.46 Million | $1.52 Billion | $160.60 Million | 0.40x | 3.75x |
| 2025 | $864.28 Million | $1.55 Billion | $165.19 Million | 0.56x | 5.23x |
Competitor Companies of 003020 by Market Capitalization
Companies near Hefei Lifeon Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see Hefei Lifeon Pharmaceutical Co Ltd (003020) total assets for a full breakdown of the balance sheet.
Key companies related to Hefei Lifeon Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Hefei Lifeon Pharmaceutical Co Ltd (2020–2026)
Market capitalization of Hefei Lifeon Pharmaceutical Co Ltd from 2020 to today. Between 2020 and today, Hefei Lifeon Pharmaceutical Co Ltd's market cap moved from $528.91 Million to $ 501.27 Million, with a yearly change of -0.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥501.27 Million | -42.00% |
| 2025 | CN¥864.28 Million | +43.46% |
| 2024 | CN¥602.46 Million | -21.34% |
| 2023 | CN¥765.85 Million | +14.78% |
| 2022 | CN¥667.21 Million | -6.39% |
| 2021 | CN¥712.72 Million | +34.75% |
| 2020 | CN¥528.91 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hefei Lifeon Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $501.27 Million USD |
| MoneyControl | $501.27 Million USD |
| MarketWatch | $501.27 Million USD |
| marketcap.company | $501.27 Million USD |
| Reuters | $501.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethy… Read more